Determining elements of remission that predict long term outcomes (GLISTEN)

Study identification

• EU PAS number:
  EUPAS1000001156
• Study ID:
  1000001156
• Official title and acronym:
  Determining elements of remission that predict long term outcomes (GLISTEN)
• DARWIN EU® study:
  No
• Study countries:
  Argentina

  Belgium

  Brazil

  Bulgaria

  Canada

  Colombia

  Ecuador

  Estonia

  Germany

  Greece

  Hungary

  India

  Ireland

  Italy

  Japan

  Korea, Republic of

  Kuwait

  Mexico

  Netherlands

  Norway

  Poland

  Portugal

  Saudi Arabia

  Singapore

  Spain

  Switzerland

  Taiwan

  United Arab Emirates

  United Kingdom

  United States
• Study description:
  Determine the relative contribution of remission domains and respective thresholds in predicting long-term outcomes in adults with severe asthma who initiate biologic therapy
• Study status:
  Ongoing

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Observational and Pragmatic Research Institute, Singapore

Study timelines

Date when funding contract was signed

Planned:17/11/2023

Actual:17/11/2023

Study start date

Planned:01/02/2026

Actual:01/02/2026

Date of final study report

Planned:31/01/2027

Sources of funding

Other

Pharmaceutical company and other private sector 

More details on funding

Pharmaceutical companies: AstraZeneca
Other: Optimum Patient Care Global

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable